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S U M M A R Y
We present a case of post-neurosurgical ventriculitis caused by carbapenemase-producing Enterobacter
cloacae successfully treated with intraventricular colistin. Enterobacter spp are intrinsically resistant to
aminopenicillins, cefazolin, and cefoxitin due to the production of constitutive chromosomal AmpC beta-
lactamases. Moreover, extended-spectrum beta-lactamase-producing Enterobacter spp have been
identified in the USA and Europe, and carbapenems are considered the drug of choice in these cases. Our
isolate was sensitive only to fosfomycin, tigecycline, and colistin, and 6 days of intravenous colistin had
failed to eradicate the infection. This case provides clinical evidence to support the administration of
intraventricular colistin in such patients.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. All rights reserved.
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Enterobacter spp are significant causes of nosocomial infections
and are intrinsically resistant to aminopenicillins, cefazolin, and
cefoxitin due to the production of constitutive chromosomal AmpC
beta-lactamases. Moreover, extended-spectrum beta-lactamase
(ESBL)-producing Enterobacter spp, particularly Enterobacter cloa-
cae, have been identified in the USA and Europe, and carbapenems
are considered the drug of choice in these cases.1 We describe here
a case of post-neurosurgical ventriculitis caused by carbapene-§ This is an open-access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-No Derivative Works License, which
permits non-commercial use, distribution, and reproduction in any medium,
provided the original author and source are credited.
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http://dx.doi.org/10.1016/j.ijid.2013.11.012mase-producing E. cloacae successfully treated with intraventric-
ular colistin.
2. Case report
A 5-year-old boy (weighing 20 kg), successfully operated for
astrocytoma, was brought to hospital 4 days after the intervention
because of a cerebrospinal fluid (CSF) leak from the surgical wound
and fever. On admission, physical examination revealed a
temperature of 40 8C, a pulse of 104 beats per min, a respiratory
rate of 22 breaths per min, and a blood pressure of 94/52 mmHg.
He was alert and oriented to time and place. Neither clinical signs
of meningeal irritation nor focal neurological signs were present.
Laboratory examinations revealed a white blood cell count of
13.15  109/l with 69% neutrophils and 19% lymphocytes. C-
reactive protein (CRP) was 5.16 mg/dl (normal values <0.5 mg/dl)
and procalcitonin 0.88 mg/l (normal values <0.5 mg/l). Results ofn behalf of International Society for Infectious Diseases. All rights reserved.
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drawn and results were subsequently negative. The wound was
revised and a sample of CSF was drawn from the cerebral
ventricles. CSF was turbid with a glucose concentration of 10 mg/
dl, a protein level of 180 mg/dl (normal values 15–45 mg/dl), and a
white cell count of 2.24  109/l with 95% neutrophils. Gram
staining of CSF revealed no organisms. Pending the culture results
the patient was empirically treated with intravenous ceftazidime
(500 mg/6 h) and teicoplanin (200 mg/day). Culture of CSF yielded
E. cloacae subsp. cloacae, which was identified using the Vitek-2
system (bioMe´rieux Inc.). The isolate was sensitive to fosfomycin
(minimum inhibitory concentration (MIC) 16 mg/l), tigecycline
(MIC 1 mg/l), and colistin (MIC 0.5 mg/l); it exhibited interme-
diate sensitivity to amikacin (MIC 16 mg/l) and was resistant to
amoxicillin–clavulanate (MIC 32 mg/l), piperacillin–tazobactam
(MIC 128 mg/l), cefotaxime (MIC 64 mg/l), cefepime (MIC
64 mg/l), ertapenem (MIC 8 mg/l), meropenem (MIC 16 mg/l),
gentamicin (MIC 16 mg/l), ciprofloxacin (MIC 4 mg/l), and
trimethoprim–sulfamethoxazole (MIC 320 mg/l). Analysis of
beta-lactamase genes by PCR and sequencing revealed the
presence of blaVIM-1, blaTEM-1, and blaSHV-12.
1
Once the organism was identified and antimicrobial suscepti-
bility testing obtained (4 days later), ceftazidime and teicoplanin
were substituted with a combination of intravenous colistin
methanesulfonate (2 000 000 IU/12 h) and intravenous rifampin
(400 mg/day). Due to the persistence of the CSF leak, the surgical
wound underwent surgical revision two times and then an
external ventricular derivation catheter was positioned. At 10
days after the first surgical revision (and 6 days of intravenous
colistin) the patient continued to be febrile and the CSF culture was
still positive for E. cloacae subsp. cloacae. Parenteral therapy was
then discontinued and intraventricular colistin methanesulfonate
125 000 IU (10 mg)/day was started. The colistin dose was diluted
in 5 ml of sterile normal saline and given through the ventricular
drainage after removal of an equal volume of CSF. After each dose,
the ventricular drainage was clamped for 1 h and released. The
patient became afebrile 48 h after beginning intraventricular
colistin. CSF cultures performed daily became negative after 2
days. After a further 5 days, the CSF culture was still sterile, with a
CSF white cell count of 6  106/l. Hence the ventricular drainage
was closed and the therapy stopped. At that time laboratory
examinations revealed a white blood cell count of 6.15  109/l
with 41% neutrophils, a CRP of 0.18 mg/dl, and procalcitonin of
<0.05 mg/l. After another 5 days, the ventricular drainage was
removed. No complications or side effects or major changes in
laboratory data were observed during the treatment. The patient
was then discharged from the hospital with moderate neurological
consequences (he walks awkwardly on the right side requiring a
small amount of support for balance disorders and has a horizontal
nystagmus), and has been followed-up for 6 months, with no
evidence of relapse or CSF leak.
3. Discussion
Carbapenem-resistant Enterobacteriaceae have been reported
worldwide, largely as a consequence of the acquisition ofcarbapenemase genes. However, to the best of our knowledge,
no other cases of carbapenemase-producing E. cloacae ventriculitis
or meningitis have been reported in the international literature.
Our strain was susceptible only to colistin, fosfomycin, and
tigecycline. Intraventricular colistin has been used successfully to
treat multidrug-resistant Acinetobacter baumannii meningitis and
ventriculitis.2 In our patient, 6 days of intravenous colistin failed to
cure the ventriculitis, while CSF culture became negative after only
2 days of intraventricular colistin. The penetration of colistin into
CSF is poor, both in patients with non-inflamed meninges and in
those with inflamed meninges.
Recent pharmacokinetic studies have demonstrated that the
intravenous administration of colistin in critically ill patients with
external ventricular drainage- associated ventriculitis caused by
Gram-negative bacteria provides a maximum concentration of
colistin in the CSF of 11% that present in serum.3 Probably, as
suggested by Ziaka et al., it would be best to administer a combined
intravenous–intraventricular treatment. In fact, higher levels in
CSF throughout the dosing interval are obtained with this
approach, and a high level of colistin may be crucial in controlling
multidrug-resistant infections.3 A further advantage of the use of
combined intravenous–intraventricular treatment would be the
possibility of curing other possible undiagnosed infectious foci.2
Fosfomycin crosses maximally into CSF in the presence of
inflamed meninges. However, its activity seems to be reduced in
human CSF.4 Moreover, fosfomycin was not available in our
hospital. Tigecycline is currently not recommended in cases of
meningeal infections, based on data showing modest penetration
into the CSF in healthy volunteers.5 Even though recent data
suggest a higher penetration of tigecycline into the CSF in cases of
inflamed meninges than in non-inflamed meninges, drug levels
may remain too low for efficient treatment of meningitis at the
studied dose level of 50 mg twice daily.5
In conclusion, our case report, in addition to documenting the
occurrence of carbapenemase-producing E. cloacae ventriculitis for
the first time, provides clinical evidence to support the adminis-
tration of intraventricular colistin in such patients.
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